Business Description
Mesoblast Ltd
ISIN : AU000000MSB8
Share Class Description:
ASX:MSB: Ordinary SharesTotal Employee Number:
81Compare
Compare
Traded in other countries / regions
MSB.AustraliaMESO.USALWB.Germany Index Membership
S&P/ASX 200 IPO Date
2004-12-16Description
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.37 | |||||
Equity-to-Asset | 0.74 | |||||
Debt-to-Equity | 0.22 | |||||
Debt-to-EBITDA | N/A |
N/A
|
N/A
| |||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 111.3 | |||||
3-Year EBITDA Growth Rate | 30.1 | |||||
3-Year EPS without NRI Growth Rate | 25 | |||||
3-Year FCF Growth Rate | 26.2 | |||||
3-Year Book Growth Rate | -10.5 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 53.25 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 24.25 | |||||
9-Day RSI | 37.51 | |||||
14-Day RSI | 43.91 | |||||
3-1 Month Momentum % | 8.78 | |||||
6-1 Month Momentum % | -3.04 | |||||
12-1 Month Momentum % | 5.19 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.43 | |||||
Quick Ratio | 2.09 | |||||
Cash Ratio | 0.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -14.8 | |||||
Shareholder Yield % | 0.06 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
FCF Margin % | -38.68 | |||||
OCF Margin % | -37.9 | |||||
3-Year ROIIC % | 52.02 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | N/A |
N/A
|
N/A
| |||
Forward PE Ratio | 200 | |||||
PE Ratio without NRI | N/A |
N/A
|
N/A
| |||
PS Ratio | 16.89 | |||||
PB Ratio | 3.57 | |||||
EV-to-EBIT | -60.79 | |||||
EV-to-Forward-EBIT | -50.33 | |||||
EV-to-EBITDA | -60.79 | |||||
EV-to-Forward-EBITDA | -64.4 | |||||
EV-to-Revenue | 18.71 | |||||
EV-to-Forward-Revenue | 14.04 | |||||
EV-to-FCF | -48.38 | |||||
Earnings Yield (Greenblatt) % | -1.65 | |||||
FCF Yield % | -2.14 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mesoblast Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 171.116 | ||
| EPS (TTM) (A$) | - | ||
| Beta | -0.2327 | ||
| 3-Year Sharpe Ratio | 0.88 | ||
| 3-Year Sortino Ratio | 2.64 | ||
| Volatility % | 27.4 | ||
| 14-Day RSI | 43.91 | ||
| 14-Day ATR (A$) | 0.12157 | ||
| 20-Day SMA (A$) | 2.374 | ||
| 12-1 Month Momentum % | 5.19 | ||
| 52-Week Range (A$) | 1.88 - 3.31 | ||
| Shares Outstanding (Mil) | 1,298.55 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mesoblast Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mesoblast Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2027 | 2027-02-26 17:00 | In 173 days | ||
| Second quarter earnings results for 2027 | 2027-02-26 | In 172 days | ||
| General meeting for 2026 | 2026-11-25 10:30 | In 80 days | ||
| Fourth quarter earnings conference call for 2026 | 2026-08-27 08:30 | 2.36 (-2.07%) | ||
| Annual report for 2026 | 2026-08-27 | 2.36 (-2.07%) | ||
| Fourth quarter earnings results for 2026 | 2026-08-27 | 2.36 (-2.07%) | ||
| inaugural R&D Day | 2026-04-08 08:00 | 1.99 (-7.24%) | ||
| Second quarter earnings conference call for 2026 | 2026-02-26 17:00 | 2.35 (+0.86%) | ||
| Second quarter earnings results for 2026 | 2026-02-26 | 2.35 (+0.86%) | ||
| Piper Sandler 37th Annual Healthcare Conference | 2025-12-04 12:00 | 2.52 (-1.18%) |
Show
Entries
Mesoblast Ltd Frequently Asked Questions
What is Mesoblast Ltd(ASX:MSB)'s stock price today?
The current price of ASX:MSB is A$2.23. The 52 week high of ASX:MSB is A$3.31 and 52 week low is A$1.88.
When is next earnings date of Mesoblast Ltd(ASX:MSB)?
The next earnings date of Mesoblast Ltd(ASX:MSB) is 2026-11-27 Est..
Does Mesoblast Ltd(ASX:MSB) pay dividends? If so, how much?
Mesoblast Ltd(ASX:MSB) does not pay dividend.
Press Release
Articles on Mesoblast Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers